Daniela Acerbi

1.1k total citations
59 papers, 872 citations indexed

About

Daniela Acerbi is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology. According to data from OpenAlex, Daniela Acerbi has authored 59 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 19 papers in Physiology and 15 papers in Pharmacology. Recurrent topics in Daniela Acerbi's work include Inhalation and Respiratory Drug Delivery (23 papers), Asthma and respiratory diseases (18 papers) and Respiratory and Cough-Related Research (8 papers). Daniela Acerbi is often cited by papers focused on Inhalation and Respiratory Drug Delivery (23 papers), Asthma and respiratory diseases (18 papers) and Respiratory and Cough-Related Research (8 papers). Daniela Acerbi collaborates with scholars based in Italy, France and United Kingdom. Daniela Acerbi's co-authors include Gianluigi Poli, Paolo Ventura, P Schiantarelli, Thomas Meyer, C Herpich, Ivano Rondelli, Knut Sommerer, G. Brambilla, Ioannis Kottakis and Raffaella Monno and has published in prestigious journals such as The American Journal of Cardiology, European Respiratory Journal and Clinical Pharmacokinetics.

In The Last Decade

Daniela Acerbi

56 papers receiving 824 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Acerbi Italy 18 463 360 117 113 77 59 872
Ashish Sharma India 15 352 0.8× 288 0.8× 48 0.4× 56 0.5× 18 0.2× 46 874
Alexander Chun United States 17 60 0.1× 340 0.9× 65 0.6× 86 0.8× 55 0.7× 28 909
François Chevanne France 22 81 0.2× 91 0.3× 68 0.6× 352 3.1× 73 0.9× 31 906
L S Schanker 9 334 0.7× 80 0.2× 46 0.4× 150 1.3× 20 0.3× 16 561
Naomi Yagi Japan 12 123 0.3× 68 0.2× 25 0.2× 110 1.0× 47 0.6× 81 539
Lawrence S. Olanoff United States 17 95 0.2× 73 0.2× 141 1.2× 162 1.4× 82 1.1× 27 823
Matthew S. Halquist United States 19 124 0.3× 307 0.9× 117 1.0× 69 0.6× 102 1.3× 73 1.3k
Richard B.R. Muijsers Netherlands 12 100 0.2× 297 0.8× 81 0.7× 25 0.2× 14 0.2× 15 712
Patrick K. Noonan United States 20 40 0.1× 184 0.5× 105 0.9× 280 2.5× 50 0.6× 40 901
Anthony R. DiSanto United States 15 69 0.1× 62 0.2× 135 1.2× 86 0.8× 67 0.9× 32 596

Countries citing papers authored by Daniela Acerbi

Since Specialization
Citations

This map shows the geographic impact of Daniela Acerbi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Acerbi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Acerbi more than expected).

Fields of papers citing papers by Daniela Acerbi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Acerbi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Acerbi. The network helps show where Daniela Acerbi may publish in the future.

Co-authorship network of co-authors of Daniela Acerbi

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Acerbi. A scholar is included among the top collaborators of Daniela Acerbi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Acerbi. Daniela Acerbi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Stephanie, David Christopher, Göran Långström, et al.. (2018). Performance of the Population Bioequivalence (PBE) Statistical Test Using an IPAC-RS Database of Delivered Dose from Metered Dose Inhalers. AAPS PharmSciTech. 19(3). 1410–1425. 4 indexed citations
2.
Singh, Dave, et al.. (2017). Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study. International Journal of COPD. Volume 12. 2001–2014. 7 indexed citations
3.
Chawes, Bo, Mirco Govoni, Eskil Kreiner‐Møller, et al.. (2014). Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. Respiratory Medicine. 108(8). 1108–1116. 9 indexed citations
4.
Acerbi, Daniela, et al.. (2013). Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers. European Respiratory Journal. 42(Suppl 57). P736–P736. 1 indexed citations
5.
6.
7.
Singh, Dave, et al.. (2011). Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. British Journal of Clinical Pharmacology. 72(6). 932–939. 23 indexed citations
8.
Backer, Wilfried De, A. Devolder, Gianluigi Poli, et al.. (2010). Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23(3). 137–148. 132 indexed citations
9.
Bousquet, Jean, et al.. (2009). Systemic Exposure and Implications for Lung Deposition with an Extra-Fine Hydrofluoroalkane Beclometasone Dipropionate/Formoterol Fixed Combination. Clinical Pharmacokinetics. 48(6). 347–358. 22 indexed citations
10.
Häußermann, Sabine, Daniela Acerbi, Peter Brand, et al.. (2007). Lung Deposition of Formoterol HFA (Atimos ® /Forair ® ) in Healthy Volunteers, Asthmatic and COPD Patients. Journal of Aerosol Medicine. 20(3). 331–341. 32 indexed citations
11.
Woodcock, Ashley, Daniela Acerbi, & Gianluigi Poli. (2002). Modulite® technology: pharmacodynamic and pharmacokinetic implications. Respiratory Medicine. 96. S9–S15. 35 indexed citations
12.
Acerbi, Daniela, S. Canali, C. Giachetti, et al.. (1998). 14C-NaVP and14C-PEV repeated dose study in rat pharmacokinetic study in rats after repeated oral administrations of14C-valproic acid sodium salt and14C-valproic acid pivaloyl oxymethyl ester. European Journal of Drug Metabolism and Pharmacokinetics. 23(2). 223–229.
13.
Rosillon, Dominique, et al.. (1998). Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. European Journal of Drug Metabolism and Pharmacokinetics. 23(2). 197–202. 12 indexed citations
14.
Acerbi, Daniela, Gianluigi Poli, & Paolo Ventura. (1998). Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes. European Journal of Drug Metabolism and Pharmacokinetics. 23(2). 172–177. 2 indexed citations
15.
16.
Zanelli, Ugo, Paola Puccini, Daniela Acerbi, Paolo Ventura, & Pier Giovanni Gervasi. (1996). Induction of peroxisomal β-oxidation and P-450 4A-dependent activities by pivalic and trichloroacetic acid in rat liver and kidney. Archives of Toxicology. 70(3-4). 145–149. 20 indexed citations
17.
Stockis, Armel, et al.. (1995). Oral bioavailability of CHF1194, an inclusion complex of piroxicam and ?-cyclodextrin, in healthy subjects under single dose and steady-state conditions. European Journal of Clinical Pharmacology. 47(6). 531–6. 18 indexed citations
18.
Rondelli, Ivano, et al.. (1994). Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 653(1). 17–23. 44 indexed citations
19.
Pabst, G, et al.. (1994). Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 19(1). 59–69. 11 indexed citations
20.
Civelli, Maurizio, T. Viganò, Daniela Acerbi, et al.. (1991). Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Inflammation Research. 33(3-4). 233–239. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ashish Sharma Breakdown of academic impact, for papers by Alexander Chun Breakdown of academic impact, for papers by François Chevanne Breakdown of academic impact, for papers by L S Schanker Breakdown of academic impact, for papers by Naomi Yagi Breakdown of academic impact, for papers by Lawrence S. Olanoff Breakdown of academic impact, for papers by Matthew S. Halquist Breakdown of academic impact, for papers by Richard B.R. Muijsers Breakdown of academic impact, for papers by Patrick K. Noonan Breakdown of academic impact, for papers by Anthony R. DiSanto
Rankless by CCL
2026